Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2015년 10월 19일
18:15
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim GmbH announced the U.S. Food and Drug Administration (FDA) granted approval of Praxbind® (idarucizumab).[4] Praxbind® is indicated for patients treated with Pradaxa® (dabigatran etexilate), when reversal of the anticoagulant effe
건강
제약
개발
2015년 10월 9일
12:45
Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066*, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psori
건강
제약
개발
2015년 10월 8일
17:35
Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists[1]
A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. 79% stated that delayed diagnosis will delay initiating tr
건강
제약
조사연구
2015년 9월 30일
17:20
New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF
An interim analysis of the INPULSIS®-ON extension trial has confirmed the efficacy and safety of OFEV®* (nintedanib) previously observed in the INPULSIS® trials.[1] The results were presented at the European Respiratory Society (ERS) International Co
건강
제약
개발
2015년 9월 29일
13:35
COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS
Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO® 1&2 indicates that Spiolto® Respimat® provides significant quality of life
건강
제약
개발
2015년 9월 29일
13:15
VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone
Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSC
건강
제약
개발
2015년 9월 29일
12:50
CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)
Today, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending European approval of idarucizumab (to be marketed as Praxbind®).[1] Idarucizumab is intended for use in
건강
제약
선언/의견
2015년 9월 21일
17:20
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD
Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approache
건강
제약
제휴
2015년 9월 21일
15:35
ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments
Boehringer Ingelheim will present new data from its broad respiratory portfolio, which includes recently approved Spiolto® Respimat® (tiotropium/olodaterol) for COPD, OFEV® (nintedanib) for IPF and Spiriva® Respimat® (tiotropium) in asthma, at the up
건강
제약
사업계획
2015년 9월 18일
13:20
Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
Boehringer Ingelheim and Eli Lilly and Company’s (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to stand
건강
제약
개발
2015년 9월 8일
17:50
Boehringer Ingelheim: New Data Show That More Than 50% of Patients and Carers Struggled to Cope with Challenges of Living with Lung Cancer
The Global Lung Cancer Coalition (GLCC) presented, at the 16th World Conference on Lung Cancer (WCLC) in Denver, USA, results of Lung Cancer: We’re Listening, a global campaign, supported by Boehringer Ingelheim. The global survey intended to increas
건강
제약
조사연구
2015년 8월 31일
09:30
ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim
The European Society of Cardiology (ESC) today announced the launch of the competitive medical research programme ‘ESC Grants for Medical Research Innovation’, exclusively supported by an independent grant from Boehringer Ingelheim. The programme aim
건강
제약
공모/모집
2015년 8월 25일
17:40
FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung
Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted filing applications for afatinib for the treatment of patients with advanced SCC of the lung progressing
건강
제약
개발
2015년 8월 21일
09:45
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults wi
건강
제약
개발
2015년 8월 19일
17:20
CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European label for Giotrif® (afatinib*), strengthening and b
건강
제약
개발
2015년 8월 17일
17:05
New data show Spiolto Respimat provides meaningful quality of life improvements in COPD
Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352 (https://goo.gl/SvaXth)/NCT02006732 (https://goo.gl/F7UiIQ)), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consiste
건강
제약
개발
2015년 7월 29일
12:10
Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer
Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today announced an exclusive license and collaboration agreement for the development and global commercialisation rights, except South Korea, China and Hong Kong, of HM61713, a novel 3rd generatio
건강
제약
제휴
2015년 7월 16일
11:00
Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis - An Update of the 2011 Guideline which suggests that clinicians use OFEV® (nintedanib*) in p
건강
제약
개발
2015년 7월 7일
09:15
Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib)
Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung Boehringer Ingelh
건강
제약
개발
2015년 7월 2일
15:25
New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries
Boehringer Ingelheim today announced regulatory authority approvals for Spiolto® Respimat® (tiotropium/olodaterol) in first European countries†. Spiolto® Respimat® is a once-daily maintenance treatment to relieve symptoms in adult patients with chron
건강
제약
개발
2015년 6월 23일
10:10
Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study
Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the anticoagulant effect of dabigatran (Pradaxa®) in patients requiring urgent anticoagulant reversal. No safety c
건강
제약
개발
2015년 6월 16일
17:20
New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers
Today, The Lancet published results from a healthy volunteer study investigating the reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) by its specific reversal agent idarucizumab. The study showed that idarucizumab led to immedi
건강
제약
개발
2015년 6월 8일
17:50
Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care
New research shows that the quality of patient-physician communication, at the moment when additional oral type 2 diabetes (T2D) medication is prescribed (‘add-on’), is linked to future patient self-care and well-being. Data from the IntroDia™ Survey
건강
제약
개발
2015년 6월 8일
17:45
Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
A Phase III clinical trial has found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes (T2D). Boehringer Ingelheim and Eli Lilly and Company presented these findings in a late-breaking poster
건강
제약
개발
2015년 6월 3일
18:10
NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication
Boehringer Ingelheim today announced that following a review by the National Institute for Health and Care Excellence (NICE) in the UK, VARGATEF® (nintedanib*) in combination with docetaxel has been recommended for use within the National Health Serv
건강
제약
개발
이전
8
9
10
11
12
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기